Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.15) by 33.91 percent. This is a 19.15 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $14.63 million which missed the analyst consensus estimate of $32.22 million by 54.60 percent. This is a 57.90 percent decrease over sales of $34.75 million the same period last year.